This website tells you more about Creon and
Pancreatic Exocrine Insufficiency
As a company dedicated to the health of the world’s 7 billion people, Mylan continues to closely monitor the COVID-19 situation in the UK. At present, we do not have any disruption in the supply of Creon (Micro, 10K, 25K). We will keep our dedicated website, www.creon.co.uk updated should anything change.
Creon capsules are interchangeable, and patients can achieve the higher dose by taking more of the lower strength capsules. Patients should not be concerned about the efficacy when switching to a lower strength capsule.
Mylan is unable to make any specific treatment recommendations to healthcare professionals or for individual patients, however, it is recommended that patients speak to their treating physician to discuss treatment options according to their health needs and their relevant clinical history.
Creon is a Pancreatic Enzyme Replacement Therapy (PERT) that helps patients with Pancreatic Exocrine Insufficiency (PEI) to break down food and digest nutrients by replacing the pancreatic enzymes made by a healthy pancreas. The active substance of Creon is pancreatin, a natural substance from the pancreas of the pig; as a biologic product Creon is produced using a complex manufacturing process that is subject to high standards and strict requirements in terms of quality and compliance.
If you require additional information or have any questions, please contact our medical information team on 01707 853 000 or via email: email@example.com
Please select from below depending on whether you are
a Creon patient, or a UK Healthcare Professional
This website is intended for use by UK Healthcare Professionals and patients who have been prescribed Creon